公开(公告)号：US12084710B2

公开(公告)日：2024-09-10

申请号：US17161221

申请日：2021-01-28

Applicant: enicor GmbH

Inventor： Harald Leyser

IPC: C12Q1/56 ,  B01L3/02 ,  G01N33/49 ,  G01N33/86

CPC classification number: C12Q1/56 ,  B01L3/0275 ,  G01N33/4905 ,  G01N33/86

Abstract: A diagnostic kit for viscoelastic analysis of a sample includes a pipette tip containing constituent (A) and a measurement cup containing constituent (B), wherein the constituents (A) and (B) are adapted to form a diagnostic composition upon combination, wherein the diagnostic composition includes an activator of coagulation and a calcium salt. A method of performing a viscoelastic analysis on a sample using such a diagnostic kit is also disclosed.

公开(公告)号：US11746348B2

公开(公告)日：2023-09-05

申请号：US17396028

申请日：2021-08-06

Applicant: GENTIUM S.R.L.

Inventor： Terenzio Ignoni ,  Vijay Kumar ,  Khalid Islam

IPC: C12N15/11 ,  C12N9/68 ,  A61K31/711 ,  A61K38/36 ,  C12Q1/37 ,  C12Q1/56 ,  G01N33/86

CPC classification number: C12N15/11 ,  A61K31/711 ,  C12Q1/37 ,  C12Q1/56 ,  G01N33/86 ,  C12N2310/127

Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27 to 32 IU/mg and, more preferably, from 28 to 32 IU/mg.

公开(公告)号：US20230265483A1

公开(公告)日：2023-08-24

申请号：US18010076

申请日：2021-06-10

Applicant: Alexion Pharmaceuticals, Inc.

Inventor： Joel Freeberg ,  Genmin Lu ,  Pamela Conley

IPC: C12Q1/56 ,  G01N33/52 ,  G01N33/86

CPC classification number: C12Q1/56 ,  G01N33/52 ,  G01N33/86

Abstract: The present disclosure relates kits and methods for measuring the potency of an andexanet sample in neutralizing a factor Xa inhibitor and restoring the activity of a wild-type factor Xa.

公开(公告)号：US20230251175A1

公开(公告)日：2023-08-10

申请号：US18192544

申请日：2023-03-29

Applicant: ENICOR GMBH

Inventor： Harald Leyser

IPC: G01N11/14 ,  C12Q1/56 ,  G01N33/49 ,  G01N33/86

CPC classification number: G01N11/14 ,  C12Q1/56 ,  G01N33/4905 ,  G01N33/86 ,  G01N2011/002

Abstract: The present invention provides an apparatus for use in viscoelastic analysis, for example in coagulation testing of sample liquids, such as blood and/or its elements. In the apparatus for use in viscoelastic analysis, the rotating means are provided below the cup, pin and cup receiving element. The present invention further provides capacitive detection means and temperature control devices, which may be used in the apparatus for use in viscoelastic analysis. The present invention further provides a method of performing viscoelastic analysis, e.g. coagulation analysis, on a sample using the devices and apparatuses.

公开(公告)号：US20190204325A1

公开(公告)日：2019-07-04

申请号：US16314672

申请日：2017-06-29

Applicant: BEIJING YOUAN HOSPITAL, CAPITAL MEDICAL UNIVERSITY ,  BEIJING INSTITUTE OF HEPATOLOGY ,  Beijing Houde Tiancheng Biotech Ltd.

Inventor： Aiying ZHANG ,  Ronghua JIN ,  Ning LI ,  Shengqi WANG ,  Yang KE

IPC: G01N33/574 ,  G01N33/566 ,  G01N33/58

CPC classification number: G01N33/57438 ,  C12Q1/56 ,  G01N33/521 ,  G01N33/543 ,  G01N33/566 ,  G01N33/582 ,  G01N33/86 ,  G01N2333/974

Abstract: A protein chip, kit and preparation method thereof for detecting abnormal decarboxy prothrombin in serum, a substrate carrier of the protein chip is provided with a plurality of detection subareas; wherein each detection subarea is used for detecting a serum sample, and is internally provided with a detection-spot area and a control-spot area, and the detection-spot area has a detection spot formed by spraying a trace amount of a DCP-specific antibody, the control-spot area has a control spot formed by spraying a bovine serum albumin; all the detection spots within one of the detection-spot area have the same material concentration, to form each of the detection spots, a total volume of 3-5 nl of the DCP-specific antibody with a concentration of 3-5 mg/mL is used; each of the detection spots is formed by a non-contact spotter, performing 6-10 spot sprays and spraying 300-500 pL in each spray.

公开(公告)号：US20180334672A1

公开(公告)日：2018-11-22

申请号：US15844801

申请日：2017-12-18

Applicant: GENTIUM S.R.L.

Inventor： Terenzio IGNONI ,  Vijay KUMAR ,  Khalid ISLAM

IPC: C12N15/11 ,  G01N33/86 ,  C12Q1/37 ,  A61K31/711 ,  C12Q1/56

CPC classification number: C12N15/11 ,  A61K31/711 ,  C12N2310/127 ,  C12Q1/37 ,  C12Q1/56 ,  G01N33/86

Abstract: It is disclosed a method for determining the biological activity of defibrotide, which comprises the steps of: a) bringing into contact defibrotide, mammalian euglobulin and a substrate specific for the plasmin which, by reaction with the plasmin, provides a measurable product; and b) measuring the amount of product formed at successive times, to thereby determine the biological activity of the defibrotide. Liquid defibrotide formulations are also disclosed, preferably water solutions, having a defined biological activity and, in particular, having an activity of 25 to 35 IU/mg of defibrotide, preferably from 27.5 to 32.5 IU/mg and, more preferably, from 28 to 32 IU/mg.

公开(公告)号：US20180188195A1

公开(公告)日：2018-07-05

申请号：US15738754

申请日：2016-06-27

Applicant: T2 Biosystems, Inc.

Inventor： Eugenio DAVISO ,  Lucius (Tad) FOX ,  Thomas Jay LOWERY, Jr. ,  Joseph MARTURANO ,  Vyacheslav PAPKOV ,  Al SCHROFF ,  Roger SMITH ,  Zhixiang LUO

IPC: G01N24/08 ,  G01R33/44 ,  C12Q1/56

CPC classification number: G01N24/088 ,  C12Q1/56 ,  G01N24/08 ,  G01N2333/974 ,  G01R33/448

Abstract: The invention features a diagnostic platform utilizing T2 magnetic resonance to directly measure integrated reactions in whole blood samples such as clotting, fibrinogen, clot contraction, and fibrinolysis to provide a comprehensive assessment of hemostatic parameters on a single instrument in minutes. The methods of the invention can be performed with less than 1 ml of blood and minimal sample handling.

公开(公告)号：US20170336424A1

公开(公告)日：2017-11-23

申请号：US15601677

申请日：2017-05-22

Applicant: Debiopharm International S.A.

Inventor： Amar Rida ,  Nicolas Mermod ,  Patrice Francois ,  Vladimir Lazarevic ,  Jacques Schrenzel

IPC: G01N33/86 ,  C12Q1/56 ,  G01N33/569

CPC classification number: G01N33/86 ,  C12Q1/56 ,  G01N33/56938 ,  G01N2333/75 ,  G01N2333/974

Abstract: A method for separating target molecules or particles from a fibrinogen containing sample comprises: (a) trapping the said target molecules or particles in a fibrin network by converting at least partially the fibrinogen contained in the sample into fibrin; (b) retracting the said fibrin network to form a fibrin clot; (c) separating the said fibrin clot from the surrounding sample medium,

公开(公告)号：US09789166B2

公开(公告)日：2017-10-17

申请号：US14799423

申请日：2015-07-14

Applicant: Paul A. Gurbel

Inventor： Paul A. Gurbel

IPC: A61K38/36 ,  C12Q1/56 ,  G01N33/86 ,  G01N33/569 ,  A61K31/4365 ,  A61K31/715

CPC classification number: A61K38/36 ,  A61K31/4365 ,  A61K31/715 ,  C12Q1/56 ,  G01N33/56966 ,  G01N33/86

Abstract: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value. In other embodiments, risk of thrombosis in a patient is evaluated in the context of a profile generated from values obtained from one or more assays that evaluate various factors associated with thrombosis and/or atherosclerosis.

公开(公告)号：US09739733B2

公开(公告)日：2017-08-22

申请号：US14648124

申请日：2013-12-05

Applicant: T2 Biosystems, Inc.

Inventor： Walter W. Massefski, Jr. ,  Thomas Jay Lowery, Jr. ,  Lynell R. Skewis

IPC: G01N24/08 ,  C12Q1/56 ,  G01R33/465 ,  G01N33/49 ,  G06F19/00 ,  G01R33/44

CPC classification number: G01N24/088 ,  C12Q1/56 ,  G01N33/4905 ,  G01N2333/75 ,  G01N2800/224 ,  G01R33/448 ,  G01R33/465 ,  G06F19/00 ,  G16H50/20 ,  Y02A90/26

Abstract: The invention features a method of monitoring a clotting process by measuring a signal characteristic of the NMR relaxation of water in a sample undergoing clotting to produce NMR relaxation data and determining from the NMR relaxation data a magnetic resonance parameter of water in the sample characteristic of the clots being formed.